Anaptys Announces Participation in December Investor Conferences

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:

GlobeNewsWire • Nov 25, 2025

AnaptysBio shares tumble after legal fight with GSK over cancer drug license

Shares of AnaptysBio fell 14% in premarket trading on Friday after the U.S. drug developer and Tesaro, a unit of Britain's GSK , filed lawsuits against each other, with both claiming a breach in a partnership deal for a cancer drug.

Reuters • Nov 21, 2025

Anaptys Announces $100 Million Stock Repurchase Plan

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an amended Stock Repurchase Plan under which the Company may repurchase up to $100.0 million of the Company's outstanding common stock, par value $0.001 per share. This amendment is in addition to the $6.4 million that remained as of Nov. 20, 2025 under the current $75.0 million Stock Repurchase Plan of which Anaptys has repurchased a total of 3,443,188 shares of common stock (11.2% shares outstanding before the start of this repurchase plan). Excluding any additional potential purchases under this Stock Repurchase Plan, Anaptys anticipates ending 2025 with approximately $300 million in cash, cash equivalents and investments, including an anticipated accrual of a one-time $75 million commercial sales milestone in Q4 2025 due from GSK once Jemperli achieves $1 billion in worldwide net sales.

GlobeNewsWire • Nov 21, 2025

AnaptysBio Buckles After Trading Legal Barbs With Pharma Giant GSK

AnaptysBio stock buckled Friday after the biotech company and GSK filed competing lawsuits against one another over a licensing deal.

Investors Business Daily • Nov 21, 2025

GSK unit sues AnaptysBio in row over Jemperli rights

GSK PLC (LSE:GSK, NYSE:GSK) has stepped up a dispute over rights to its fast-growing cancer drug Jemperli by having its US subsidiary Tesaro sue AnaptysBio in the Delaware Court of Chancery. Tesaro is asking the court to confirm that alleged breaches of their 2014 licence deal allow it to end the current contract, keep a perpetual licence to the medicine and cut by half the royalty and milestone payments it owes AnaptysBio.

Proactive Investors • Nov 21, 2025

GSK Unit Tesaro Sues AnaptysBio, Threatening Key Cancer Drug Jemperli Royalties

GSK plc (NYSE: GSK) subsidiary, Tesaro Inc., has initiated litigation against AnaptysBio, Inc. (NASDAQ: ANAB) in the Delaware Chancery Court.

Benzinga • Nov 21, 2025

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chancery Court, requesting a court declaration that TESARO, Inc. (“Tesaro”) has materially breached the parties' Collaboration and Exclusive License Agreement (“Collaboration Agreement”) and that GSK (Tesaro's corporate parent) has tortiously interfered with the Collaboration Agreement. Anaptys has requested that the court declare that Anaptys is entitled to all rights and remedies under the Collaboration Agreement.

GlobeNewsWire • Nov 21, 2025

GSK, AnaptysBio Sue Each Other Over Cancer Drug License

The companies accuse one another of breaching a licensing agreement for Jemperli, a drug used to treat some forms of endometrial cancer.

WSJ • Nov 21, 2025

AnaptysBio: Maintaining 'Hold' As RA Program Still In Play With ANB033 Advancement

AnaptysBio receives a "Hold" rating after discontinuing rosnilimab for ulcerative colitis, saving $10 million but maintaining focus on rheumatoid arthritis. ANAB plans to advance rosnilimab for RA, with a program update expected in the first half of 2026, seeking non-dilutive funding or a strategic partner. Development of CD122 antagonist ANB033 for Celiac Disease continues in phase 1b, targeting a large unmet market with a clinically validated approach from several other companies with IL-15/CD122 targeting.

Seeking Alpha • Nov 13, 2025

Why AnaptysBio Stock Plummeted, Reversing A 70% Monthlong Run

AnaptysBio stock plummeted Monday, reversing a recent run, after its experimental ulcerative colitis drug failed in midstage testing.

Investors Business Daily • Nov 10, 2025